Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 5 (2008), Issue 3 (March)

1. Menopause.
   Lancet, 371(9614): 760-70. [Abstract] [Full-text]
2. Clinical outcomes after an unstructured treatment interruption in children and adolescents with perinatally acquired HIV infection.
   Pediatrics, 121(3): e513-21. [Abstract] [Full-text]
3. Effect of computer order entry on prevention of serious medication errors in hospitalized children.
   Pediatrics, 121(3): e421-7. [Abstract] [Full-text]
4. Rates of medication errors among depressed and burnt out residents: prospective cohort study.
   BMJ, 336(7642): 488-91. [Abstract] [Full-text]
5. Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer.
   J Urol, 179(3): 911-5; discussion 915-6. [Abstract] [Full-text]
6. A review of stimuli-responsive nanocarriers for drug and gene delivery.
   J Control Release, 126(3): 187-204. [Abstract] [Full-text]
7. Injectable chitosan hydrogels for localised cancer therapy.
   J Control Release, 126(3): 205-16. [Abstract] [Full-text]
8. Ultrasound assisted siRNA delivery using PEG-siPlex loaded microbubbles.
   J Control Release, 126(3): 265-73. [Abstract] [Full-text]
9. Study on controlled drug permeation of magnetic-sensitive ferrogels: effect of Fe3O4 and PVA.
   J Control Release, 126(3): 228-36. [Abstract] [Full-text]
10. Liposomes-mediated delivery of pro-apoptotic therapeutic membrane proteins.
    J Control Release, 126(3): 217-27. [Abstract] [Full-text]
11. Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice.
    J Control Release, 126(3): 246-54. [Abstract] [Full-text]
12. Bio-nanocapsule conjugated with liposomes for in vivo pinpoint delivery of various materials.
    J Control Release, 126(3): 255-64. [Abstract] [Full-text]
13. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
    Cancer, 112(5): 1001-10. [Abstract] [Full-text]
14. Maternal characteristics associated with pregnancy exposure to FDA category C, D, and X drugs in a Canadian population.
    Pharmacoepidemiol Drug Saf, 17(3): 270-7. [Abstract] [Full-text]
15. Pharmacokinetics and selectivity of porphyrin synthesis after topical application of hexaminolevulinate in patients with cervical intraepithelial neoplasia.
    Am J Obstet Gynecol, 198(3): 300.e1-7. [Abstract] [Full-text]
16. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
    Int J Cancer, 122(9): 2148-53. [Abstract] [Full-text]
17. Evidence of a novel docetaxel sensitizer, garlic-derived S-allylmercaptocysteine, as a treatment option for hormone refractory prostate cancer.
    Int J Cancer, 122(9): 1941-8. [Abstract] [Full-text]
18. The combination of epigallocatechin gallate and curcumin suppresses ER alpha-breast cancer cell growth in vitro and in vivo.
    Int J Cancer, 122(9): 1966-71. [Abstract] [Full-text]
19. The role of postoperative adjuvant chemotherapy following curative resection for gastric cancer: a meta-analysis.
    Cancer Invest, 26(3): 317-25. [Abstract] [Full-text]
20. Screening for drug abuse among medical and nonmedical users of prescription drugs in a probability sample of college students.
    Arch Pediatr Adolesc Med, 162(3): 225-31. [Abstract] [Full-text]
21. Influence of therapy on the antioxidant status in patients with melanoma.
    J Clin Pharm Ther, 33(2): 179-85. [Abstract] [Full-text]
22. A 3-year study of medication incidents in an acute general hospital.
    J Clin Pharm Ther, 33(2): 109-14. [Abstract] [Full-text]
23. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma.
    Breast J, 14(2): 141-6. [Abstract] [Full-text]
24. Inpatient insulin therapy.
    Curr Opin Endocrinol Diabetes Obes, 15(2): 159-66. [Abstract] [Full-text]
25. Sensor-augmented pump therapy in type 1 diabetes.
    Curr Opin Endocrinol Diabetes Obes, 15(2): 118-22. [Abstract] [Full-text]
26. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.
    JAMA, 299(9): 1036-45. [Abstract] [Full-text]
27. Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine.
    Ophthalmology, 115(3): 483-7. [Abstract] [Full-text]
28. Short- and long-term effects of growth hormone on the heart.
    Int J Cardiol, 124(3): 393-4. [Abstract] [Full-text]
29. Sitagliptin: a novel agent for the management of type 2 diabetes mellitus.
    Am J Health Syst Pharm, 65(6): 521-31. [Abstract] [Full-text]
30. Protocol-based medical management of post-ERCP pancreatitis.
    J Gastroenterol Hepatol, 23(3): 385-92. [Abstract] [Full-text]
31. Complete response of CNS-involved olfactory neuroendocrine tumor using multimodal therapy.
    Onkologie, 31(3): 119-21. [Abstract] [Full-text]
32. Early prediction of therapy outcome in patients with high-risk soft tissue sarcoma using positron emission tomography.
    Onkologie, 31(3): 107-12. [Abstract] [Full-text]
33. Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model.
    BJU Int, 101(7): 884-8. [Abstract] [Full-text]
34. Neoadjuvant and adjuvant strategies for pancreatic cancer.
    Eur J Surg Oncol, 34(3): 297-305. [Abstract] [Full-text]
35. The AJT report.
    Am J Transplant, 8(4): 731-2. [Abstract] [Full-text]
36. Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agents.
    J Clin Oncol, 26(8): 1324-30. [Abstract] [Full-text]
37. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.
    J Clin Oncol, 26(8): 1316-23. [Abstract] [Full-text]
38. Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib.
    J Clin Oncol, 26(8): 1253-9. [Abstract] [Full-text]
39. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
    J Clin Oncol, 26(8): 1216-22. [Abstract] [Full-text]
40. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse.
    J Clin Oncol, 26(8): 1208-15. [Abstract] [Full-text]
41. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
    J Clin Oncol, 26(8): 1231-8. [Abstract] [Full-text]
42. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
    J Clin Oncol, 26(8): 1275-81. [Abstract] [Full-text]
43. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.
    J Clin Oncol, 26(8): 1223-30. [Abstract] [Full-text]
44. A percutaneous coronary intervention-thrombolytic predictive instrument to assist choosing between immediate thrombolytic therapy versus delayed primary percutaneous coronary intervention for acute myocardial infarction.
    Am J Cardiol, 101(6): 790-5. [Abstract] [Full-text]
45. Potential for interactions between dietary supplements and prescription medications.
    Am J Med, 121(3): 207-11. [Abstract] [Full-text]
46. Arterial thrombosis in children.
    Expert Rev Cardiovasc Ther, 6(3): 419-28. [Abstract] [Full-text]
47. Electrospinning: applications in drug delivery and tissue engineering.
    Biomaterials, 29(13): 1989-2006. [Abstract] [Full-text]
48. Adjuvant chemotherapy after resection in elderly Medicare and Medicaid patients with colon cancer.
    Arch Intern Med, 168(5): 521-9. [Abstract] [Full-text]
49. Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum.
    Ann Surg Oncol, 15(4): 1107-16. [Abstract] [Full-text]
50. EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients.
    Int J Gynecol Cancer, 18(2): 357-62. [Abstract] [Full-text]
51. Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary.
    Int J Gynecol Cancer, 18(2): 379-83. [Abstract] [Full-text]
52. Weekly cisplatin with oral etoposide: a well-tolerated and highly effective regimen in relapsed ovarian cancer.
    Int J Gynecol Cancer, 18(2): 228-34. [Abstract] [Full-text]
53. Potential impact of Medicare Part D in the end-stage renal disease population.
    Adv Chronic Kidney Dis, 15(2): 140-6. [Abstract] [Full-text]
54. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.
    Proc Natl Acad Sci U S A, 105(10): 3879-84. [Abstract] [Full-text]
55. Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN.
    Proc Natl Acad Sci U S A, 105(10): 3690-5. [Abstract] [Full-text]
56. Hydrophilic biodegradable microspheres of interferon-alpha and its pharmacokinetics in mice.
    J Biomed Mater Res B Appl Biomater, 85(1): 225-30. [Abstract] [Full-text]
57. Dacarbazine-Doxorubicin therapy ameliorated an extremely aggressive mesenteric desmoid tumor associated with familial adenomatous polyposis: report of a case.
    Jpn J Clin Oncol, 38(3): 222-6. [Abstract] [Full-text]
58. Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
    Jpn J Clin Oncol, 38(3): 176-81. [Abstract] [Full-text]
59. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.
    Cancer Res, 68(6): 1970-8. [Abstract] [Full-text]
60. Growth in HIV-infected children receiving antiretroviral therapy at a pediatric infectious diseases clinic in Uganda.
    AIDS Patient Care STDS, 22(3): 245-51. [Abstract] [Full-text]
61. Improving outcomes for patients with Burkitt lymphoma and HIV.
    AIDS Patient Care STDS, 22(3): 175-87. [Abstract] [Full-text]
62. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals.
    AIDS Patient Care STDS, 22(3): 233-43. [Abstract] [Full-text]
63. Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.
    Cancer Lett, 262(2): 232-8. [Abstract] [Full-text]
64. Best practice policy statement on urologic surgery antimicrobial prophylaxis.
    J Urol, 179(4): 1379-90. [Abstract] [Full-text]
65. Chemotherapeutic agents and the skin: An update.
    J Am Acad Dermatol, 58(4): 545-70. [Abstract] [Full-text]
66. Developing an adverse drug reaction reporting system at a teaching hospital.
    Basic Clin Pharmacol Toxicol, 102(4): 408-11. [Abstract] [Full-text]
67. The use of fluorescence microscopy to define polymer localisation to the late endocytic compartments in cells that are targets for drug delivery.
    J Control Release, 127(1): 1-11. [Abstract] [Full-text]
68. Temoporfin-loaded invasomes: development, characterization and in vitro skin penetration studies.
    J Control Release, 127(1): 59-69. [Abstract] [Full-text]
69. Mechanistic model for drug release during the lag phase from pellets coated with a semi-permeable membrane.
    J Control Release, 127(1): 31-40. [Abstract] [Full-text]
70. Preservation of the active lactone form of irinotecan using drug eluting beads for the treatment of colorectal cancer metastases.
    J Control Release, 127(1): 70-8. [Abstract] [Full-text]
71. Thermo-sensitive and biodegradable hydrogels based on stereocomplexed Pluronic multi-block copolymers for controlled protein delivery.
    J Control Release, 127(1): 22-30. [Abstract] [Full-text]
72. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice.
    J Control Release, 127(1): 41-9. [Abstract] [Full-text]
73. Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation.
    J Neurol Neurosurg Psychiatry, 79(4): 467-70. [Abstract] [Full-text]
74. Cell-penetrating peptides: from molecular mechanisms to therapeutics.
    Biol Cell, 100(4): 201-17. [Abstract] [Full-text]
75. Thrombolytic evacuation of post-craniotomy epidural haematomas using closed suction drains: a pilot study.
    Acta Neurochir (Wien), 150(4): 359-66; discussion 366. [Abstract] [Full-text]
76. Making medicines in the early modern household.
    Bull Hist Med, 82(1): 145-68. [Abstract] [Full-text]
77. Pediatric fingertip injuries: do prophylactic antibiotics alter infection rates?
    Pediatr Emerg Care, 24(3): 148-52. [Abstract] [Full-text]
78. Local thrombolysis in patients with dural venous thrombosis unresponsive to heparin.
    J Stroke Cerebrovasc Dis, 17(2): 95-100. [Abstract] [Full-text]
79. Intravenous recombinant tissue plasminogen activator improves arterial recanalization rates and reduces infarct volumes in patients with hyperdense artery sign on baseline computed tomography.
    J Stroke Cerebrovasc Dis, 17(2): 64-8. [Abstract] [Full-text]
80. Vertebrobasilar revascularization rates and outcomes in the MERCI and multi-MERCI trials.
    J Stroke Cerebrovasc Dis, 17(2): 55-7. [Abstract] [Full-text]
81. Cerebral venous thrombosis: analysis of a multicenter cohort from the United States.
    J Stroke Cerebrovasc Dis, 17(2): 49-54. [Abstract] [Full-text]
82. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus.
    J Pediatr, 152(4): 582-4. [Abstract] [Full-text]
83. Health plan notification and feedback to providers is associated with increased filling of preventer medications for children with asthma enrolled in Medicaid.
    J Pediatr, 152(4): 481-8. [Abstract] [Full-text]
84. Photodynamic therapy using 5-aminolaevulinic acid for the treatment of dysplasia in Barrett's oesophagus.
    Expert Opin Pharmacother, 9(5): 851-8. [Abstract] [Full-text]
85. Combined anti-proliferative and anti-angiogenic strategies for cancer.
    Expert Opin Pharmacother, 9(5): 701-15. [Abstract] [Full-text]
86. Development of an aryl hydrocarbon receptor antagonist using the proteolysis-targeting chimeric molecules approach: a potential tool for chemoprevention.
    Mol Pharmacol, 73(4): 1064-71. [Abstract] [Full-text]
87. Exploiting complexity and the robustness of network architecture for drug discovery.
    J Pharmacol Exp Ther, 325(1): 1-9. [Abstract] [Full-text]
88. Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users.
    J Clin Oncol, 26(9): 1537-43. [Abstract] [Full-text]
89. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.
    J Clin Oncol, 26(9): 1532-6. [Abstract] [Full-text]
90. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97.
    J Clin Oncol, 26(9): 1504-10. [Abstract] [Full-text]
91. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study.
    J Clin Oncol, 26(9): 1496-503. [Abstract] [Full-text]
92. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
    J Clin Oncol, 26(9): 1465-71. [Abstract] [Full-text]
93. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.
    J Clin Oncol, 26(9): 1443-51. [Abstract] [Full-text]
94. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    J Clin Oncol, 26(9): 1435-42. [Abstract] [Full-text]
95. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
    J Clin Oncol, 26(9): 1427-34. [Abstract] [Full-text]
96. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    J Clin Oncol, 26(9): 1404-10. [Abstract] [Full-text]
97. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
    J Natl Cancer Inst, 100(6): 388-98. [Abstract] [Full-text]
98. Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer.
    Diagn Mol Pathol, 17(1): 34-8. [Abstract] [Full-text]
99. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
    J Clin Oncol, 26(9): 1519-25. [Abstract] [Full-text]
100. PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients.
     Pharmacogenomics J, 8(2): 139-46. [Abstract] [Full-text]
101. The yeast two-hybrid system and its role in drug discovery.
     Expert Opin Ther Targets, 12(4): 505-15. [Abstract] [Full-text]
102. Targeting survivin in cancer therapy.
     Expert Opin Ther Targets, 12(4): 463-76. [Abstract] [Full-text]
103. Therapeutic targets for medulloblastoma.
     Expert Opin Ther Targets, 12(4): 449-61. [Abstract] [Full-text]
104. Potential therapeutic targets for Parkinson's disease.
     Expert Opin Ther Targets, 12(4): 425-36. [Abstract] [Full-text]
105. Cysteinyl leukotriene receptor CysLT1 as a novel therapeutic target for allergic rhinitis treatment.
     Expert Opin Ther Targets, 12(4): 415-23. [Abstract] [Full-text]
106. Identifying targets for drug discovery using bioinformatics.
     Expert Opin Ther Targets, 12(4): 383-9. [Abstract] [Full-text]
107. Risk factors for the use of prescription antibiotics on UK broiler farms.
     J Antimicrob Chemother, 61(4): 947-52. [Abstract] [Full-text]
108. Online monitoring of pulse pressure variation to guide fluid therapy after cardiac surgery.
     Anesth Analg, 106(4): 1201-6, table of contents. [Abstract] [Full-text]
109. Molecular effectors and modulators of hypericin-mediated cell death in bladder cancer cells.
     Oncogene, 27(13): 1916-29. [Abstract] [Full-text]
110. Topical photodynamic therapy of murine non-melanoma skin carcinomas with aluminum phthalocyanine chloride and a diode laser: pharmacokinetics, tumor response and cosmetic outcomes.
     Photodermatol Photoimmunol Photomed, 24(2): 87-94. [Abstract] [Full-text]
111. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.
     Expert Opin Biol Ther, 8(4): 527-40. [Abstract] [Full-text]
112. Novel agents for muscle-invasive and advanced urothelial cancer.
     BJU Int, 101(8): 937-43. [Abstract] [Full-text]
113. Influence of intraventricular fibrinolytic therapy with rt-PA on the long-term outcome of treated patients with spontaneous basal ganglia hemorrhage: a case-control study.
     Eur J Neurol, 15(4): 342-9. [Abstract] [Full-text]
114. Will changing maintenance intravenous fluid from 0.18% to 0.45% saline do more harm than good?
     Arch Dis Child, 93(4): 335-40. [Abstract] [Full-text]
115. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer.
     Ann Thorac Surg, 85(4): 1217-23; discussion 1223-4. [Abstract] [Full-text]
116. Highly active antiretroviral therapy use and HIV transmission risk behaviors among individuals who are HIV infected and were recently released from jail.
     Am J Public Health, 98(4): 661-6. [Abstract] [Full-text]
117. Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women.
     Hypertension, 51(4): 1115-22. [Abstract] [Full-text]
118. Proteasome activity as a target of hormone replacement therapy-dependent plaque stabilization in postmenopausal women.
     Hypertension, 51(4): 1135-41. [Abstract] [Full-text]
119. Educational interventions to reduce prescribing errors.
     Arch Dis Child, 93(4): 313-5. [Abstract] [Full-text]
120. Hyponatraemia and hypokalaemia during intravenous fluid administration.
     Arch Dis Child, 93(4): 285-7. [Abstract] [Full-text]
121. Barium enema evaluation of colonic involvement in endometriosis.
     AJR Am J Roentgenol, 190(4): 1050-4. [Abstract] [Full-text]
122. Fluoroscopic intralesional injection with pingyangmycin lipiodol emulsion for the treatment of orbital venous malformations.
     AJR Am J Roentgenol, 190(4): 966-71. [Abstract] [Full-text]
123. Bupropion differentially impacts acquisition of methamphetamine self-administration and sucrose-maintained behavior.
     Pharmacol Biochem Behav, 89(3): 463-72. [Abstract] [Full-text]
124. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
     Lancet, 371(9617): 1007-16. [Abstract] [Full-text]
125. Outcome of treatment with Hyper-CVAD regimen in Chinese patients with acute lymphocytic leukemia.
     Leuk Res, 32(6): 930-5. [Abstract] [Full-text]
126. Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A.
     Eur J Endocrinol, 158(4): 483-90. [Abstract] [Full-text]
127. Development of a metropolitan matrix of primary stroke centers: the Phoenix experience.
     Stroke, 39(4): 1246-53. [Abstract] [Full-text]
128. Gender differences in stroke examined in a 10-year cohort of patients admitted to a Canadian teaching hospital.
     Stroke, 39(4): 1090-5. [Abstract] [Full-text]
129. Gel electrophoretic analysis of corneal collagen after photodynamic cross-linking treatment.
     Cornea, 27(3): 353-6. [Abstract] [Full-text]
130. Effect of complete epithelial debridement before riboflavin-ultraviolet-A corneal collagen crosslinking therapy.
     J Cataract Refract Surg, 34(4): 657-61. [Abstract] [Full-text]
131. Long-term delivery enhances in vivo osteogenic efficacy of bone morphogenetic protein-2 compared to short-term delivery.
     Biochem Biophys Res Commun, 369(2): 774-80. [Abstract] [Full-text]
132. Lysozyme-dextran core-shell nanogels prepared via a green process.
     Langmuir, 24(7): 3486-92. [Abstract] [Full-text]
133. Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies.
     Cancer, 112(7): 1600-6. [Abstract] [Full-text]
134. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
     Cancer, 112(7): 1529-37. [Abstract] [Full-text]
135. Encapsulation of methylene blue in polyacrylamide nanoparticle platforms protects its photodynamic effectiveness.
     Biochem Biophys Res Commun, 369(2): 579-83. [Abstract] [Full-text]
136. Functionalization of carbon nanotubes enables non-covalent binding and intracellular delivery of small interfering RNA for efficient knock-down of genes.
     Biochem Biophys Res Commun, 369(2): 595-602. [Abstract] [Full-text]
137. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
     Cancer, 112(7): 1555-61. [Abstract] [Full-text]
138. Symptom burden after autologous stem cell transplantation for multiple myeloma.
     Cancer, 112(7): 1617-24. [Abstract] [Full-text]
139. A comparison of pentane-1,5-diol to other diols for use in dermatology.
     Expert Opin Investig Drugs, 17(4): 601-10. [Abstract] [Full-text]
140. Vinflunine: clinical perspectives of an emerging anticancer agent.
     Expert Opin Investig Drugs, 17(4): 583-91. [Abstract] [Full-text]
141. Replacement therapy for Addison's disease: recent developments.
     Expert Opin Investig Drugs, 17(4): 497-509. [Abstract] [Full-text]
142. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.
     Ann Oncol, 19(4): 769-73. [Abstract] [Full-text]
143. p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer.
     Ann Oncol, 19(4): 660-8. [Abstract] [Full-text]
144. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
     Ann Oncol, 19(4): 734-8. [Abstract] [Full-text]
145. ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study.
     Ann Oncol, 19(4): 763-8. [Abstract] [Full-text]
146. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
     Ann Oncol, 19(4): 801-6. [Abstract] [Full-text]
147. Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.
     Ann Oncol, 19(4): 739-45. [Abstract] [Full-text]
148. Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer.
     Ann Oncol, 19(4): 729-33. [Abstract] [Full-text]
149. p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-alpha and melphalan.
     Ann Oncol, 19(4): 793-800. [Abstract] [Full-text]
150. Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma.
     Ann Oncol, 19(4): 752-62. [Abstract] [Full-text]
151. Iron complexes of dendrimer-appended carboxylates for activating dioxygen and oxidizing hydrocarbons.
     J Am Chem Soc, 130(13): 4352-63. [Abstract] [Full-text]
152. Hollow silica nanocontainers as drug delivery vehicles.
     Langmuir, 24(7): 3417-21. [Abstract] [Full-text]
153. Fractionated aminolevulinic acid-photodynamic therapy provides additional evidence for the use of PDT for non-melanoma skin cancer.
     J Eur Acad Dermatol Venereol, 22(4): 426-30. [Abstract] [Full-text]
154. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
     Ann Hematol, 87(5): 361-7. [Abstract] [Full-text]
155. Local photodynamic therapy for equine squamous cell carcinoma: evaluation of a novel treatment method in a murine model.
     Vet J, 176(2): 170-6. [Abstract] [Full-text]
156. Simple microwire and microcatheter mechanical thrombolysis with adjuvant intraarterial urokinase for treatment of hyperacute ischemic stroke patients.
     Acta Radiol, 49(3): 351-7. [Abstract] [Full-text]
157. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
     Gynecol Oncol, 109(1): 33-8. [Abstract] [Full-text]
158. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
     Gynecol Oncol, 109(1): 97-106. [Abstract] [Full-text]
159. Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels.
     Oncology, 73(1): 90-7. [Abstract] [Full-text]
160. Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer.
     Oncology, 73(1): 76-80. [Abstract] [Full-text]
161. Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002).
     Oncology, 73(1): 65-71. [Abstract] [Full-text]
162. Large institutional experience with dose-intensive chemotherapy and stem cell support in the management of sarcoma patients.
     Oncology, 73(1): 58-64. [Abstract] [Full-text]
163. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
     Oncology, 73(1): 9-20. [Abstract] [Full-text]
164. Delay in presentation and reperfusion therapy in ST-elevation myocardial infarction.
     Am J Med, 121(4): 316-23. [Abstract] [Full-text]
165. Perioperative fluid restriction reduces complications after major gastrointestinal surgery.
     Surgery, 143(4): 466-8. [Abstract] [Full-text]
166. Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery.
     Nanomed, 3(2): 247-65. [Abstract] [Full-text]
167. Carbon nanotubes filled with a chemotherapeutic agent: a nanocarrier mediates inhibition of tumor cell growth.
     Nanomed, 3(2): 175-82. [Abstract] [Full-text]
168. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
     Lancet Oncol, 9(4): 352-8. [Abstract] [Full-text]
169. Paclitaxel associated with cholesterol-rich nanoemulsions promotes atherosclerosis regression in the rabbit.
     Atherosclerosis, 197(2): 959-66. [Abstract] [Full-text]
170. Increased lipoprotein remnant cholesterol levels in HIV-positive patients during antiretroviral therapy.
     Atherosclerosis, 198(1): 192-7. [Abstract] [Full-text]
171. Functionalized injectable hydrogels for controlled insulin delivery.
     Biomaterials, 29(16): 2527-34. [Abstract] [Full-text]
172. Poly(beta-amino ester) as a carrier for si/shRNA delivery in lung cancer cells.
     Biomaterials, 29(16): 2535-47. [Abstract] [Full-text]

© 2004-2008 Chemotherapy Research Today. All Rights Reserved.